Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.

Abstract

Necrolytic migratory erythema (NME) is a classical paraneoplastic symptom observed in patients with pancreatic glucagonoma. We report a 46-year-old Japanese woman with glucagonoma who presented with mucocutaneous manifestations 1 year prior to the diagnosis of the pancreatic neoplasm with multiple liver metastases. She was treated with octreotide long-acting release, a somatostatin analog, which resulted in a dramatic improvement of NME within 2 weeks after the start of treatment. Increased awareness of NME may avoid unnecessary delay in the diagnosis of pancreatic glucagonoma.

• Authors: Shiro Kimbara, Yutaka Fujiwara, Masanori Toyoda, Naoko Chayahara, Yoshinori Imamura, Naomi Kiyota, Toru Mukohara, Atsushi Fukunaga, Masahiro Oka, Chikako Nishigori, Hironobu Minami
• Journal: Clinical journal of gastroenterology (Clin J Gastroenterol) Vol. 7 Issue 3 Pg. 255-9 (Jun 2014) ISSN: 1865-7265 [Electronic] Japan
• PMID: 26183746 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Octreotide

Topics

• Antineoplastic Agents, Hormonal (therapeutic use)
• Female
• Glucagonoma (complications)
• Humans
• Middle Aged
• Necrolytic Migratory Erythema (drug therapy, etiology)
• Octreotide (therapeutic use)
• Pancreatic Neoplasms (etiology)
• Remission Induction
• Time Factors